{"pmid":32387864,"title":"SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects.","text":["SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects.","BACKROUND AND AIMS: According to the World Obesity Federation, \"obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)\"; additionally the Centres for Disease Control and Prevention reported that \"people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness\". Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection. METHODS: Pubmed search on obesity and SARS-CoV-2 infection. RESULTS: We present \"mechanistic\" obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative inflammatory/metabolic links between these diseases. CONCLUSION: Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese.","Diabetes Metab Syndr","Michalakis, Konstantinos","Ilias, Ioannis","32387864"],"abstract":["BACKROUND AND AIMS: According to the World Obesity Federation, \"obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)\"; additionally the Centres for Disease Control and Prevention reported that \"people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness\". Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection. METHODS: Pubmed search on obesity and SARS-CoV-2 infection. RESULTS: We present \"mechanistic\" obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative inflammatory/metabolic links between these diseases. CONCLUSION: Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese."],"journal":"Diabetes Metab Syndr","authors":["Michalakis, Konstantinos","Ilias, Ioannis"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387864","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.dsx.2020.04.033","keywords":["coronavirus","glucose","human","infection","inflammation","obesity"],"locations":["obese"],"topics":["Mechanism"],"weight":1,"_version_":1666428892678717440,"score":9.490897,"similar":[{"pmid":32417709,"title":"Mechanism of inflammatory response in associated comorbidities in COVID-19.","text":["Mechanism of inflammatory response in associated comorbidities in COVID-19.","BACKGROUND AND AIMS: The outbreak of the new coronavirus, SARS-CoV-2, causes a respiratory disease and individuals with pre-existing cardiometabolic disorders display worse prognosis through the infection course. The aim of this minireview is to present epidemiological data related to metabolic comorbidities in association with the SARS-CoV-2. METHODS: This is a narrative mini-review with Pubmed search until April 23, 2020 using the keywords COVID-19, SARS-CoV-2, treatment of coronavirus and following terms: diabetes mellitus, obesity, arterial hypertension, ACE-inhibitors, cytokine storm, immune response and vitamin D. RESULTS: Studies indicate that obese individuals are more likely to develop infections, and that adipose tissue serves as a pathogen reservoir. In diabetic individuals higher rate of inflammatory processes is seen due to constant glucose recognition by C type lectin receptors. Hypertensive individuals, usually grouped with other conditions, are treated with drugs to reduce blood pressure mostly through ACEi and ARB, that leads to increased ACE2 expression, used by SARS-CoV-2 for human's cell entry. Until now, the studies have shown that individuals with those conditions and affected by COVID-19 present an uncontrolled release of pro-inflammatory cytokines and an unbalanced immune response, leading to the cytokine storm phenomenon. Vitamin D is highlighted as a potential therapeutic target, because in addition to acting on the immune system, it plays an important role in the control of cardiometabolic diseases. CONCLUSION: Currently, since there is no proven and effective antiviral therapy for SARS-CoV-2, the efforts should focus on controlling inflammatory response and reduce the risks of associated complications.","Diabetes Metab Syndr","de Lucena, Thays Maria Costa","da Silva Santos, Ariane Fernandes","de Lima, Brenda Regina","de Albuquerque Borborema, Maria Eduarda","de Azevedo Silva, Jaqueline","32417709"],"abstract":["BACKGROUND AND AIMS: The outbreak of the new coronavirus, SARS-CoV-2, causes a respiratory disease and individuals with pre-existing cardiometabolic disorders display worse prognosis through the infection course. The aim of this minireview is to present epidemiological data related to metabolic comorbidities in association with the SARS-CoV-2. METHODS: This is a narrative mini-review with Pubmed search until April 23, 2020 using the keywords COVID-19, SARS-CoV-2, treatment of coronavirus and following terms: diabetes mellitus, obesity, arterial hypertension, ACE-inhibitors, cytokine storm, immune response and vitamin D. RESULTS: Studies indicate that obese individuals are more likely to develop infections, and that adipose tissue serves as a pathogen reservoir. In diabetic individuals higher rate of inflammatory processes is seen due to constant glucose recognition by C type lectin receptors. Hypertensive individuals, usually grouped with other conditions, are treated with drugs to reduce blood pressure mostly through ACEi and ARB, that leads to increased ACE2 expression, used by SARS-CoV-2 for human's cell entry. Until now, the studies have shown that individuals with those conditions and affected by COVID-19 present an uncontrolled release of pro-inflammatory cytokines and an unbalanced immune response, leading to the cytokine storm phenomenon. Vitamin D is highlighted as a potential therapeutic target, because in addition to acting on the immune system, it plays an important role in the control of cardiometabolic diseases. CONCLUSION: Currently, since there is no proven and effective antiviral therapy for SARS-CoV-2, the efforts should focus on controlling inflammatory response and reduce the risks of associated complications."],"journal":"Diabetes Metab Syndr","authors":["de Lucena, Thays Maria Costa","da Silva Santos, Ariane Fernandes","de Lima, Brenda Regina","de Albuquerque Borborema, Maria Eduarda","de Azevedo Silva, Jaqueline"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417709","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.dsx.2020.05.025","keywords":["diabetes mellitus","hypertension arterial","immune response","obesity","vitamin d"],"locations":["obese"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667058206769152000,"score":418.29587},{"pmid":32459524,"title":"Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.","text":["Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.","Recent reports have shown a strong association between obesity and the severity of COVID-19 infection, even in the absence of other co-morbidities. After infecting the host cells, SARS-CoV-2 may cause a hyper-inflammatory reaction through the excessive release of cytokines, a condition known as \"cytokine storm\", while inducing lymphopenia and a disrupted immune response. Obesity is associated with chronic low-grade inflammation and immune dysregulation, but the exact mechanisms through which it exacerbates COVID-19 infection are not fully clarified. The production of increased amounts of cytokines such as TNF-alpha, IL-1, IL-6 and MCP-1 lead to oxidative stress and defective function of innate and adaptive immunity, while the activation of NLRP3 inflammasome seems to play a crucial role in the pathogenesis of the infection. Endothelial dysfunction and arterial stiffness could favor the recently discovered infection of the endothelium by SARS-CoV-2, while alterations in cardiac structure and function and the pro-thrombotic microenvironment in obesity could provide a link for the increased cardiovascular events in these patients. The successful use of anti-inflammatory agents such as IL-1 and IL-6 blockers in similar hyper-inflammatory settings like that of rheumatoid arthritis has triggered the discussion of whether such agents could be administrated in selected patients with COVID-19 disease.","Am J Physiol Endocrinol Metab","Korakas, Emmanouil","Ikonomidis, Ignatios","Kousathana, Foteini","Balampanis, Konstantinos","Kountouri, Aikaterini","Raptis, Athanasios","Palaiodimou, Lina","Kokkinos, Alexander","Lambadiari, Vaia","32459524"],"abstract":["Recent reports have shown a strong association between obesity and the severity of COVID-19 infection, even in the absence of other co-morbidities. After infecting the host cells, SARS-CoV-2 may cause a hyper-inflammatory reaction through the excessive release of cytokines, a condition known as \"cytokine storm\", while inducing lymphopenia and a disrupted immune response. Obesity is associated with chronic low-grade inflammation and immune dysregulation, but the exact mechanisms through which it exacerbates COVID-19 infection are not fully clarified. The production of increased amounts of cytokines such as TNF-alpha, IL-1, IL-6 and MCP-1 lead to oxidative stress and defective function of innate and adaptive immunity, while the activation of NLRP3 inflammasome seems to play a crucial role in the pathogenesis of the infection. Endothelial dysfunction and arterial stiffness could favor the recently discovered infection of the endothelium by SARS-CoV-2, while alterations in cardiac structure and function and the pro-thrombotic microenvironment in obesity could provide a link for the increased cardiovascular events in these patients. The successful use of anti-inflammatory agents such as IL-1 and IL-6 blockers in similar hyper-inflammatory settings like that of rheumatoid arthritis has triggered the discussion of whether such agents could be administrated in selected patients with COVID-19 disease."],"journal":"Am J Physiol Endocrinol Metab","authors":["Korakas, Emmanouil","Ikonomidis, Ignatios","Kousathana, Foteini","Balampanis, Konstantinos","Kountouri, Aikaterini","Raptis, Athanasios","Palaiodimou, Lina","Kokkinos, Alexander","Lambadiari, Vaia"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459524","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1152/ajpendo.00198.2020","keywords":["covid-19","obesity","arterial stiffness","cytokines","immune system"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967699029852161,"score":409.41522},{"pmid":32422280,"title":"Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking.","text":["Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking.","The effects of obesity and smoking in the coronavirus disease 2019 (COVID-19) pandemic remain controversial. Angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system (RAS), is the human cell receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. ACE2 expression increases on lung alveolar epithelial cells and adipose tissue due to obesity, smoking and air pollution. A significant relationship exists between air pollution and SARS-CoV-2 infection, as more severe COVID-19 symptoms occur in smokers; comorbid conditions due to obesity or excess ectopic fat accumulation as underlying risk factors for severe COVID-19 strongly encourage the virus/ACE2 receptor-ligand interaction concept. Indeed, obesity, air pollution and smoking associated risk factors share underlying pathophysiologies that are related to the Renin-Angiotensin-System in SARS-CoV-2 infection. The aim of this review is to emphasize the mechanism of receptor-ligand interaction and its impact on the enhanced risk of death due to SARS-CoV-2 infection.","Environ Toxicol Pharmacol","Engin, Ayse Basak","Engin, Evren Doruk","Engin, Atilla","32422280"],"abstract":["The effects of obesity and smoking in the coronavirus disease 2019 (COVID-19) pandemic remain controversial. Angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system (RAS), is the human cell receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. ACE2 expression increases on lung alveolar epithelial cells and adipose tissue due to obesity, smoking and air pollution. A significant relationship exists between air pollution and SARS-CoV-2 infection, as more severe COVID-19 symptoms occur in smokers; comorbid conditions due to obesity or excess ectopic fat accumulation as underlying risk factors for severe COVID-19 strongly encourage the virus/ACE2 receptor-ligand interaction concept. Indeed, obesity, air pollution and smoking associated risk factors share underlying pathophysiologies that are related to the Renin-Angiotensin-System in SARS-CoV-2 infection. The aim of this review is to emphasize the mechanism of receptor-ligand interaction and its impact on the enhanced risk of death due to SARS-CoV-2 infection."],"journal":"Environ Toxicol Pharmacol","authors":["Engin, Ayse Basak","Engin, Evren Doruk","Engin, Atilla"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422280","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.etap.2020.103411","keywords":["air pollution","angiotensin ii","angiotensin-converting-enzyme inhibitors","covid-19","obesity","smoking"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667254896722706432,"score":397.6376},{"pmid":32492562,"title":"The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.","text":["The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.","It is widely believed that infection with the SARS-CoV-2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease. Immune cells accumulate in visceral adipose tissue and together with paracrine adipocytes release a wide range of biologically active cytokines (including IL-1beta, IL5, IL6 and IL8) that can result in both local, pulmonary and systemic inflammation. A more intense 'cytokine storm' is postulated as the mechanism behind the extreme immune response seen in severe COVID-19. It is striking how dangerous the combination of obesity and COVID-19 is, resulting in a greater risk of ICU admission and a higher mortality. Furthermore, patients from a BAME background appear to have increased mortality after SARS-CoV-2 infection; they also have a higher prevalence of central obesity and its metabolic complications. In the absence of an effective vaccine, the therapeutic potential of immune-modulating drugs is a priority, but the development of new drugs is expensive and time-consuming. A more pragmatic solution would be to seek to repurpose existing drugs, particularly those that might suppress the heightened cytokine activity seen in obesity, the major risk factor for a poor prognosis in COVID-19. Montelukast is a cysteinyl leukotriene receptor antagonist licensed to treat asthma and allergic rhinitis. It has been shown to diminish pulmonary response to antigen, tissue eosinophilia and IL-5 expression in inflammatory cells. It has also been shown to decrease elevated levels of IL-1beta and IL8 in humans with viral upper respiratory tract infections compared with placebo-treated patients. In addition, in silico studies have demonstrated a high binding affinity of the montelukast molecule to the terminal site of the virus's main protease enzyme which is needed for virus RNA synthesis and replication. Montelukast, which is cheap, safe and widely available would appear to have the potential to be an ideal candidate drug for clinical trials, particularly in early stage disease before irreparable tissue damage has already occurred. HYPOTHESIS: Through a direct anti-viral effect, or by suppression of heightened cytokine release in response to SARS-CoV-2, montelukast will reduce the severity of immune-mediated multiorgan damage resulting from COVID-19, particularly in patients with central obesity and metabolic syndrome.","Med Hypotheses","Almerie, Muhammad Qutayba","Kerrigan, David Daniel","32492562"],"abstract":["It is widely believed that infection with the SARS-CoV-2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease. Immune cells accumulate in visceral adipose tissue and together with paracrine adipocytes release a wide range of biologically active cytokines (including IL-1beta, IL5, IL6 and IL8) that can result in both local, pulmonary and systemic inflammation. A more intense 'cytokine storm' is postulated as the mechanism behind the extreme immune response seen in severe COVID-19. It is striking how dangerous the combination of obesity and COVID-19 is, resulting in a greater risk of ICU admission and a higher mortality. Furthermore, patients from a BAME background appear to have increased mortality after SARS-CoV-2 infection; they also have a higher prevalence of central obesity and its metabolic complications. In the absence of an effective vaccine, the therapeutic potential of immune-modulating drugs is a priority, but the development of new drugs is expensive and time-consuming. A more pragmatic solution would be to seek to repurpose existing drugs, particularly those that might suppress the heightened cytokine activity seen in obesity, the major risk factor for a poor prognosis in COVID-19. Montelukast is a cysteinyl leukotriene receptor antagonist licensed to treat asthma and allergic rhinitis. It has been shown to diminish pulmonary response to antigen, tissue eosinophilia and IL-5 expression in inflammatory cells. It has also been shown to decrease elevated levels of IL-1beta and IL8 in humans with viral upper respiratory tract infections compared with placebo-treated patients. In addition, in silico studies have demonstrated a high binding affinity of the montelukast molecule to the terminal site of the virus's main protease enzyme which is needed for virus RNA synthesis and replication. Montelukast, which is cheap, safe and widely available would appear to have the potential to be an ideal candidate drug for clinical trials, particularly in early stage disease before irreparable tissue damage has already occurred. HYPOTHESIS: Through a direct anti-viral effect, or by suppression of heightened cytokine release in response to SARS-CoV-2, montelukast will reduce the severity of immune-mediated multiorgan damage resulting from COVID-19, particularly in patients with central obesity and metabolic syndrome."],"journal":"Med Hypotheses","authors":["Almerie, Muhammad Qutayba","Kerrigan, David Daniel"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492562","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109883","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433510944768,"score":380.31784},{"pmid":32320741,"pmcid":"PMC7166301","title":"Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.","text":["Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.","BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. METHODS: 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25kg/m(2). RESULTS: The presence of obesity in MAFLD patients was associated with a~6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p=.029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p=.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. CONCLUSIONS: Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.","Metabolism","Zheng, Kenneth I","Gao, Feng","Wang, Xiao-Bo","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Ma, Hong-Lei","Liu, Wen-Yue","George, Jacob","Zheng, Ming-Hua","32320741"],"abstract":["BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. METHODS: 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25kg/m(2). RESULTS: The presence of obesity in MAFLD patients was associated with a~6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p=.029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p=.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. CONCLUSIONS: Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD."],"journal":"Metabolism","authors":["Zheng, Kenneth I","Gao, Feng","Wang, Xiao-Bo","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Ma, Hong-Lei","Liu, Wen-Yue","George, Jacob","Zheng, Ming-Hua"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320741","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.metabol.2020.154244","keywords":["covid-19","mafld","obesity","sars-cov-2"],"locations":["obese","Wenzhou","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138493696344068,"score":360.62302}]}